Physician profile
Aaron Tea
NPI 1285097998
$2,035.36
in general payments reported to CMS, 2019-2025
21 companies · $649 in 2025
The $649 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.45 · 2022: $144 · 2023: $525 · 2024: $672 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.79 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $453.32 | 2023-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $395.89 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $296.26 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $172.07 | 2021-2025 | Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $108.27 | 2024-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $102.64 | 2025 | Cologuard Collection Kit |
| Radius Health, INC. | $78.84 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.40 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $69.80 | 2023-2024 | Arexvy, Shingrix |
| Aimmune Therapeutics, INC. | $47.58 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $46.99 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $37.68 | 2024 | Voquezna |
| Acadia Pharmaceuticals INC | $21.23 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.58 | 2024 | |
| Phadia US INC. | $17.42 | 2023 | Immunocap |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.39 | 2025 | |
| Nestle Healthcare Nutrition INC. | $16.17 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.63 | 2024 | Zoryve |
| Arbor Pharmaceuticals, INC. | $14.52 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.13 | 2023 | Quviviq |
| Novo Nordisk INC | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Tea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.